News

Public · Published

Merck's Efinopegdutide Shows Improvement In Liver Fibrosis Without Worsening Steatohepatitis

Merck announced positive results from a Phase 2b trial of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis, or MASH, and stage 2–3 liver fibrosis. The company said treatment improved liver fibrosis without worsening MASH and showed MASH resolution without worsening fibrosis at 52 weeks.

Published:

Updated:

What happened

Merck announced positive results from a Phase 2b trial of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis, or MASH, and stage 2–3 liver fibrosis. The company said treatment improved liver fibrosis without worsening MASH and showed MASH resolution without worsening fibrosis at 52 weeks.

Confirmed

Global impact / market context

Improvement in both liver scarring and MASH without worsening either condition could strengthen efinopegdutide’s case for further development. If later studies confirm the findings, Merck may have a future treatment opportunity; trial results alone do not establish approval, sales, or commercial impact.

Analyst inference

The supplied information describes a Phase 2b study, an intermediate stage of drug testing, and reports no approval, revenue, or financial guidance. Investors therefore have evidence of clinical progress, but not enough here to assess development costs, commercial demand, or effects on Merck’s earnings.

Analyst inference

What to watch

  1. Further trial results would show whether the reported improvements hold up in additional testing and clarify how consistently patients experienced better liver fibrosis without worsening MASH. Analyst inference
  2. Whether Merck advances efinopegdutide into later-stage trials is a key next step; the supplied article does not announce a development decision or trial timeline. Analyst inference
  3. Any later regulatory review or approval would determine whether the treatment could be sold; the article reports trial results, not a regulatory decision. Analyst inference

Evidence

  • Original source link unavailable